JPH08310937A - Preparation for external use - Google Patents
Preparation for external useInfo
- Publication number
- JPH08310937A JPH08310937A JP13871895A JP13871895A JPH08310937A JP H08310937 A JPH08310937 A JP H08310937A JP 13871895 A JP13871895 A JP 13871895A JP 13871895 A JP13871895 A JP 13871895A JP H08310937 A JPH08310937 A JP H08310937A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- neoagarobiose
- hair
- preparation
- agar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- JWMBOBQNPBCYER-UHFFFAOYSA-N 4-[(4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl)oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC1C(CO)OC(O)C(O)C1OC1C(O)C(C2O)OCC2O1 JWMBOBQNPBCYER-UHFFFAOYSA-N 0.000 claims abstract description 62
- 230000002087 whitening effect Effects 0.000 claims abstract description 19
- 230000003020 moisturizing effect Effects 0.000 claims description 20
- 230000000694 effects Effects 0.000 abstract description 14
- 239000002537 cosmetic Substances 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 7
- 229920001817 Agar Polymers 0.000 abstract description 6
- 239000008272 agar Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 229920000936 Agarose Polymers 0.000 abstract description 3
- 239000003599 detergent Substances 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 241000589563 Alteromonas sp. Species 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 239000003906 humectant Substances 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000003061 melanogenesis Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 238000011156 evaluation Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 239000002453 shampoo Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010014970 Ephelides Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000003351 Melanosis Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000002826 placenta Anatomy 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 229940069521 aloe extract Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- -1 packs Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- JZKFHQMONDVVNF-UHFFFAOYSA-N dodecyl sulfate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(O)(=O)=O JZKFHQMONDVVNF-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、ネオアガロビオースを
含有してなる外用剤に関し、さらに詳しくは、ネオアガ
ロビオースを含有することにより、皮膚に対する優れた
美白効果、皮膚および毛髪に対する優れた保湿効果を有
する外用剤に関する。FIELD OF THE INVENTION The present invention relates to an external preparation containing neo-agarobiose. More specifically, by containing neo-agarobiose, it has an excellent whitening effect on the skin and an excellent effect on the skin and hair. And an external preparation having a moisturizing effect.
【0002】[0002]
【従来の技術】従来、外用剤において、皮膚の色黒、く
すみ、シミ、ソバカスの防止などの美容効果を得るため
のものとして、アスコルビン酸またはその誘導体、グル
タチオン、コロイドイオウ、プラセンタエキス、当帰エ
キス、桑白皮エキス、アロエエキス等を有効成分として
配合した美白化粧料等が知られている。また、乾燥等に
よる肌荒れや髪のパサツキなどを改善するために、保湿
剤としてグリセリン、尿素、アミノ酸またはその誘導
体、ヒアルロン酸等を配合した皮膚化粧料、毛髪化粧
料、皮膚外用剤等が知られている。2. Description of the Related Art Conventionally, as an external preparation for obtaining cosmetic effects such as preventing skin darkening, dullness, spots, freckles, etc., ascorbic acid or its derivative, glutathione, colloidal sulfur, placenta extract, and so on. Whitening cosmetics and the like containing an extract, mulberry skin extract, aloe extract and the like as active ingredients are known. Further, in order to improve skin roughness due to dryness, dryness of hair, etc., skin cosmetics, hair cosmetics, external skin preparations, etc. containing glycerin, urea, amino acids or their derivatives, hyaluronic acid, etc. as moisturizers are known. ing.
【0003】[0003]
【発明が解決しようとする課題】しかしながら、美白化
粧料等において、アスコルビン酸はそれ自体が酸化され
やすいため経時的に一定の効果の発現が期待しにくく、
これを配合した化粧料等も変色しやすいという欠点があ
った。また、アスコルビン酸誘導体、プラセンタエキ
ス、当帰エキス、桑白皮エキス、アロエエキスは、これ
ら単独では効果が十分に高いとは言えず、さらに、グル
タチオンやコロイドイオウは配合後に特有の異臭を生じ
ることがあり、剤形によっては沈殿が生じる場合もある
という欠点を有していた。一方、皮膚の乾燥を防止して
肌荒れを改善したり、毛髪の乾燥を防止して髪のパサツ
キを改善するなどの保湿効果を有する外用剤において
も、グリセリン、尿素、アミノ酸またはその誘導体、ヒ
アルロン酸など従来の保湿剤を単独で使用した場合、十
分に高い効果を得るために配合量を多くすると製品の使
用感を損なう場合があった。そうした中にあり、より安
定性が良く、また皮膚に対する優れた美白効果、皮膚お
よび毛髪に対する優れた保湿効果を有する外用剤の開発
が望まれていた。However, in whitening cosmetics and the like, ascorbic acid itself is easily oxidized, so that it is difficult to expect a certain effect to be exhibited over time.
The cosmetics and the like containing this also have a drawback that they are easily discolored. In addition, ascorbic acid derivative, placenta extract, toki extract, mulberry bark extract, aloe extract are not said to be sufficiently effective alone, and glutathione and colloidal sulfur produce a peculiar offensive odor after blending. However, there is a drawback that precipitation may occur depending on the dosage form. On the other hand, glycerin, urea, amino acids or their derivatives, hyaluronic acid can also be used as an external preparation having a moisturizing effect such as preventing dryness of skin to improve rough skin, and preventing dryness of hair to improve dryness of hair. When a conventional moisturizer is used alone, increasing the blending amount to obtain a sufficiently high effect may impair the usability of the product. Under these circumstances, it has been desired to develop an external preparation which is more stable and has an excellent whitening effect on the skin and an excellent moisturizing effect on the skin and hair.
【0004】[0004]
【課題を解決するための手段】かかる実情に鑑み、本発
明者らは糖類のもつ美白作用、保湿作用等につき鋭意研
究した結果、ネオアガロビオースが高いメラニン産生抑
制作用および優れた保湿作用を併せもち、これを配合し
た外用剤が皮膚の美白効果、皮膚および毛髪の保湿効果
において優れた性質を示すことを見いだし、本発明を完
成した。In view of the above circumstances, the present inventors have diligently studied the whitening effect, the moisturizing effect and the like of saccharides, and as a result, have found that neo-agarobiose has a high melanin production inhibitory effect and an excellent moisturizing effect. In addition, the inventors have found that an external preparation containing the same exhibits excellent properties in skin whitening effect and skin and hair moisturizing effect, and completed the present invention.
【0005】すなわち、本発明はネオアガロビオースを
含有することを特徴とする外用剤である。That is, the present invention is an external preparation characterized by containing neo-agarobiose.
【0006】本発明の外用剤に用いるネオアガロビオー
スは、ヘテロ二糖の1種であり、その調製方法は特に限
定はないが、例えば次に示すように、微生物由来の特定
の寒天分解酵素を用いて寒天またはアガロースを分解
し、調製する方法が挙げられる。Neoagarobiose used in the external preparation of the present invention is one kind of heterodisaccharide, and its preparation method is not particularly limited. For example, as shown below, a specific agar-degrading enzyme derived from a microorganism is used. A method of decomposing agar or agarose with the use of and preparing.
【0007】まず、寒天分解酵素生産菌の1種であるア
ルテロモナス・エスピーE−1を常法に従って培養し、
培養液中より寒天分解酵素を得る。次に、10mMトリ
ス−塩酸緩衝溶液(pH7.5)に0.5%濃度になる
ように寒天またはアガロースを加え、これに上記寒天分
解酵素50mU/ml以上の濃度になるように添加し
て、40℃にて4時間以上作用させる。この溶液を沸騰
水中で5分間放置することにより反応を停止させ、4℃
に冷却する。ここで、特に寒天を基質とした場合には不
溶物の沈殿等が存在するため遠心分離により残渣を除去
する。得られた上澄液にネオアガロビオースが含まれる
ので、これを凍結乾燥することによりネオアガロビオー
スを得ることができる。First, Alteromonas sp. E-1 which is one of the agar-degrading enzyme-producing bacteria is cultured according to a conventional method,
Agar-degrading enzyme is obtained from the culture solution. Next, agar or agarose was added to 10 mM Tris-hydrochloric acid buffer solution (pH 7.5) so as to have a concentration of 0.5%, and the agar-degrading enzyme was added thereto at a concentration of 50 mU / ml or more, It is allowed to act at 40 ° C for 4 hours or more. The reaction is stopped by leaving this solution in boiling water for 5 minutes to stop the reaction at 4 ° C.
Cool to. Here, especially when agar is used as the substrate, insoluble matter precipitates and the like, so the residue is removed by centrifugation. Since the obtained supernatant contains neo-agarobiose, it can be lyophilized to obtain neo-agarobiose.
【0008】本発明の外用剤において、ネオアガロビオ
ースの含有量は0.0001〜30重量%(以下、特に
記載のあるもの以外は重量%を単に%で示す)であるこ
とが好ましく、特に0.01〜5%の範囲がより好まし
い。In the external preparation of the present invention, the content of neoagarobiose is preferably 0.0001 to 30% by weight (hereinafter,% by weight is simply represented by% unless otherwise specified), and particularly preferably The range of 0.01 to 5% is more preferable.
【0009】本発明の外用剤は、上記ネオアガロビオー
スの他、通常化粧品、医薬部外品、医薬品に用いられる
精製水、pH調製剤、低級アルコール、多価アルコー
ル、油剤、粉体、界面活性剤、水溶性高分子等を必要に
応じて適宜配合することにより調製され、また目的に応
じて本発明の効果を損なわない量的、質的範囲で、乳化
助剤、防腐剤、香料、緩衝液、色素等を配合することが
できる。The external preparations of the present invention include, in addition to the above neoagarobiose, purified water, pH adjusting agents, lower alcohols, polyhydric alcohols, oils, powders, and interfaces commonly used for cosmetics, quasi drugs, and pharmaceuticals. Prepared by appropriately blending an activator, a water-soluble polymer and the like, if necessary, and in a quantitative and qualitative range that does not impair the effects of the present invention depending on the purpose, an emulsification aid, a preservative, a fragrance, A buffer solution, a dye and the like can be added.
【0010】また、本発明の外用剤は、必要によりさら
に公知の薬剤を添加しても良い。この薬剤としては、例
えば、アスコルビン酸またはその誘導体、プラセンタエ
キス、当帰エキス、桑白皮エキス、アロエエキス等の美
白効果を有する薬剤;グリセリン、尿素、アミノ酸また
はその誘導体、ヒアルロン酸等の保湿効果を有する薬
剤;グリチルレチン酸またはその誘導体、インドメタシ
ン等の抗炎症剤;ベンゾフェノン、パラアミノ安息香
酸、桂皮酸またはこれら各々の誘導体等の紫外線吸収
剤;ビタミンE、ローズマリーエキス、茶エキス等の酸
化防止剤等が挙げられる。これら薬剤は単独で用いて
も、2種以上を組み合わせて用いても良い。If necessary, known agents may be added to the external preparation of the present invention. Examples of the drug include a drug having a whitening effect such as ascorbic acid or a derivative thereof, a placenta extract, a toki extract, a mulberry extract, an aloe extract; a moisturizing effect of glycerin, urea, an amino acid or a derivative thereof, hyaluronic acid and the like. Anti-inflammatory agents such as glycyrrhetinic acid or its derivatives and indomethacin; UV absorbers such as benzophenone, para-aminobenzoic acid, cinnamic acid or their respective derivatives; Antioxidants such as vitamin E, rosemary extract and tea extract Etc. These agents may be used alone or in combination of two or more kinds.
【0011】本発明の外用剤の剤形は特に限定されず、
化粧水、乳液、クリーム、パック、クレンジング料、マ
ッサージ料、美容液等のスキンケア化粧料;ファンデー
ション、口紅、頬紅等のメークアップ化粧料;洗顔料、
シャンプー、ボディソープ等の洗浄料;リンス、ヘアパ
ック等の毛髪用化粧料;軟膏剤、分散液等の皮膚外用剤
等、種々の剤形とすることができる。The dosage form of the external preparation of the present invention is not particularly limited,
Skin care cosmetics such as lotions, emulsions, creams, packs, cleansing agents, massage agents, beauty essences; makeup cosmetics such as foundations, lipsticks and blushers; facial cleanser,
Various dosage forms can be used, such as detergents for shampoos, body soaps, cosmetics for hair such as rinses and hair packs, external preparations for skin such as ointments and dispersions.
【0012】[0012]
【実施例】以下に試験例および実施例を挙げて本発明を
さらに詳細に説明するが、これらは本発明を何ら限定す
るものではない。EXAMPLES The present invention will be described in more detail below with reference to test examples and examples, but these do not limit the present invention in any way.
【0013】試験例1 メラニン産生抑制試験 2枚の6穴シャーレに培地を適量取り、B16メラノー
マを播種し、37℃、二酸化炭素濃度5%中にて静置す
る。翌日、ネオアガロビオース(注1)を最終濃度が各
々0(対照)、1、10、100μg/mlとなるよう
に検体調製液を添加混和する。培養5日目に培地を交換
し、再度検体調製液を添加する。翌日、培地を除き、1
枚のシャーレについて、細胞をPBS(リン酸緩衝液)
にて洗浄後、回収し、B16メラノーマの白色化度を評
価した。 (注1:本明細書に例示の方法にて調製したもの)Test Example 1 Melanin Production Inhibition Test An appropriate amount of the medium was placed in two 6-well petri dishes, and B16 melanoma was inoculated and allowed to stand at 37 ° C. in a carbon dioxide concentration of 5%. The next day, the sample preparation solution is added and mixed so that the final concentrations of neoagarobiose (Note 1) are 0 (control), 1, 10, and 100 μg / ml, respectively. On the 5th day of culture, the medium is exchanged and the sample preparation solution is added again. The next day, remove the medium and
Cells (PBS (phosphate buffer solution))
After washing in, it was collected and the whitening degree of B16 melanoma was evaluated. (Note 1: Prepared by the method exemplified in this specification)
【0014】白色化度の評価基準は以下に示すとおりで
ある。 ++ :プラセンタエキス100μg/ml添加時よ
り白くなった。 + :プラセンタエキス100μg/ml添加時と
同程度に白くなった。 ± :プラセンタエキス100μg/ml添加時よ
り白くならないが、対照より白くなった。 − :対照と同程度。The evaluation criteria of whitening degree are as follows. ++: It became whiter than when 100 μg / ml of placenta extract was added. +: Whitened to the same extent as when 100 μg / ml of placenta extract was added. ±: Not whiter than when 100 μg / ml of placenta extract was added, but whiter than the control. -: Similar to the control.
【0015】残りの1枚のシャーレについて、細胞をホ
ルマリン固定後、1%クリスタルバイオレット溶液を添
加し、染色する。各検体濃度に対する生存細胞数(A)
および対照の細胞数(B)を測定し、式(1)により細
胞生存率を算出した。以上の結果を表1に示す。For the remaining one dish, cells are fixed with formalin, and a 1% crystal violet solution is added for staining. Number of viable cells for each sample concentration (A)
And the cell number (B) of the control was measured, and the cell viability was calculated by the formula (1). Table 1 shows the above results.
【0016】[0016]
【式1】 (Equation 1)
【0017】[0017]
【表1】 [Table 1]
【0018】表1の結果より明らかな如く、本発明に用
いるネオアガロビオースは、B16メラノーマに対し細
胞毒性が低く、かつ高いメラニン産生抑制能を有するこ
とが認められた。このことは、皮膚においてネオアガロ
ビオースが高い美白効果を有することを示す。As is clear from the results shown in Table 1, it was confirmed that neo-agarobiose used in the present invention has low cytotoxicity to B16 melanoma and has a high melanin production suppressing ability. This indicates that neo agarobiose has a high whitening effect on the skin.
【0019】試験例2 保湿性試験 表2に示す4種の保湿剤とネオアガロビオース(注1と
同じもの)について、各々試料0.1gを精秤し、40
℃、75%の恒温恒湿槽に3日間静置する。このときの
重量を測定し、このときの重量増加率をもって保湿性を
評価した。Test Example 2 Moisture Retention Test For each of the four moisturizers and neo agarobiose (the same as in Note 1) shown in Table 2, 0.1 g of each sample was precisely weighed and 40
Let stand for 3 days in a thermo-hygrostat at 75 ° C. The weight at this time was measured, and the moisturizing property was evaluated by the weight increase rate at this time.
【0020】[0020]
【表2】 [Table 2]
【0021】表2の結果より明らかな如く、本発明に用
いるネオアガロビオースは他の保湿剤に比べて吸湿性が
高く、保湿効果に優れていた。As is clear from the results shown in Table 2, neoagarobiose used in the present invention has a higher hygroscopicity and an excellent moisturizing effect than other moisturizers.
【0022】実施例1および比較例1 乳液 下に示す組成および製法で乳液を調製し、使用試験を行
って、その美白効果および保湿作用による肌荒れ改善効
果を下記評価方法および評価基準により評価した。結果
を表3に示す。Example 1 and Comparative Example 1 Emulsion An emulsion was prepared according to the composition and the production method shown below, and a usage test was conducted to evaluate the whitening effect and the rough skin improving effect due to the moisturizing effect according to the following evaluation methods and evaluation criteria. The results are shown in Table 3.
【0023】<実施例1> (組成) (成 分) (重量%) (1)スクワラン 5 (2)ワセリン 2 (3)ミツロウ 0.5 (4)セスキオレイン酸ソルビタン 0.8 (5)ポリオキシエチレンオレイルエーテル(20E.O.) 1.2 (6)1,3−ブチレングリコール 5 (7)ネオアガロビオース(注1と同じもの) 2 (8)エチルアルコール 5 (9)防腐剤 適 量 (10)香料 適 量 (11)水酸化ナトリウム 0.1 (12)カルボキシビニルポリマー(1%水溶液) 20 (13)精製水 残 量<Example 1> (Composition) (Component) (% by weight) (1) Squalane 5 (2) Vaseline 2 (3) Beeswax 0.5 (4) Sorbitan sesquioleate 0.8 (5) Poly Oxyethylene oleyl ether (20 EO) 1.2 (6) 1,3-butylene glycol 5 (7) Neoagarobiose (same as Note 1) 2 (8) Ethyl alcohol 5 (9) Preservative Suitable Quantity (10) Perfume Suitable quantity (11) Sodium hydroxide 0.1 (12) Carboxyvinyl polymer (1% aqueous solution) 20 (13) Purified water Residual quantity
【0024】(製法) A.成分(6)〜(8)、(12)および(13)を加
熱混合し、70℃に保つ。 B.成分(1)〜(5)および(9)を加熱混合し、7
0℃に保つ。 C.BにAおよび成分(10)を加えて均一に混和した
後、(11)を加えて均一に乳化し、30℃まで冷却し
て乳液を得る。(Production Method) A. Ingredients (6)-(8), (12) and (13) are heat mixed and maintained at 70 ° C. B. The components (1) to (5) and (9) are heated and mixed, and
Keep at 0 ° C. C. After A and component (10) are added to B and mixed uniformly, (11) is added to uniformly emulsify and cool to 30 ° C. to obtain an emulsion.
【0025】<比較例1>組成は実施例1の組成からネ
オアガロビオースを除き、代わりに同量の精製水を加え
たものである。製法は実施例1の製法に準じたものであ
る。<Comparative Example 1> The composition is the composition of Example 1 except that neoagarobiose is removed, and the same amount of purified water is added instead. The manufacturing method is based on the manufacturing method of Example 1.
【0026】(評価方法)30〜50才の20名の女性
をパネルとし、実施例1、比較例1の乳液2品につい
て、2週間にわたって毎日、朝と夜の2回、洗顔後に適
量を顔面に塗布してもらった。塗布による美白効果およ
び肌荒れ改善効果を下の評価基準によって評価した。(Evaluation method) Twenty women aged 30 to 50 years were used as a panel, and two emulsions of Example 1 and Comparative Example 1 were used for 2 weeks, twice daily in the morning and night, and after washing the face, an appropriate amount was applied to the face. I got it applied to. The whitening effect and the rough skin improving effect by application were evaluated according to the following evaluation criteria.
【0027】(評価基準) [美白効果] 有 効 : シミ・ソバカス・くすみがほとんど目立
たなくなった。 やや有効 : シミ・ソバカス・くすみがあまり目立た
なくなった。 無 効 : 変わらない [肌荒れ改善効果] 有 効 : 肌のかさつきや荒れが改善された。 やや有効 : 肌のかさつきや荒れがやや改善された。 無 効 : 変わらない(Evaluation Criteria) [Whitening Effect] Effective: Spots, freckles, and dullness were almost inconspicuous. Slightly effective: Spots, freckles, and dullness are less noticeable. No effect: No change [Effect of improving rough skin] Effective: Improves the roughness and roughness of the skin. Slightly effective: The bulkiness and roughness of the skin were slightly improved. Ineffective: Does not change
【0028】[0028]
【表3】 [Table 3]
【0029】表3の結果より明らかなように、実施例1
の乳液は比較例1のものに比べ、シミ、ソバカス、くす
みの解消や肌のかさつき、荒れの改善において良好な結
果が得られ、美白効果および保湿による肌荒れ改善効果
に優れた効果を示した。As is clear from the results of Table 3, Example 1
Compared with the emulsion of Comparative Example 1, good results were obtained in the removal of spots, freckles, dullness and improvement of skin roughness and roughness, and the emulsion of Example 1 showed an excellent effect of whitening effect and rough skin improving effect by moisturizing.
【0030】実施例2および比較例2 クリーム 下に示す組成および製法でクリームを調製し、使用試験
によりその美白効果を評価した。評価方法および評価基
準は、実施例1および比較例1の方法と同じである。結
果を表4に示す。Example 2 and Comparative Example 2 Cream A cream was prepared by the composition and production method shown below, and its whitening effect was evaluated by a usage test. The evaluation method and evaluation criteria are the same as those in Example 1 and Comparative Example 1. The results are shown in Table 4.
【0031】<実施例2> (組成) (成 分) (重量%) (1)ミツロウ 6 (2)セタノール 5 (3)還元ラノリン 8 (4)スクワラン 1.5 (5)グリセリンモノステアレート 0.5 (6)親油性モノステアリン酸グリセリン 13 (7)ポリオキシエチレンソルビタンモノ ラウリン酸エステル(20E.O.) 2 (8)ネオアガロビオース(注1と同じもの) 2 (9)防腐剤 0.1 (10)香料 適 量 (11)1,3−ブチレングリコール 5 (12)精製水 残 量<Example 2> (Composition) (Component) (% by weight) (1) Beeswax 6 (2) Cetanol 5 (3) Reduced lanolin 8 (4) Squalane 1.5 (5) Glycerin monostearate 0 .5 (6) Lipophilic glyceryl monostearate 13 (7) Polyoxyethylene sorbitan monolaurate (20 EO) 2 (8) Neo agarobiose (same as Note 1) 2 (9) Preservative 0.1 (10) Perfume proper amount (11) 1,3-butylene glycol 5 (12) Purified water balance
【0032】(製法) A.成分(1)〜(7)、(9)および(10)を加熱
混合し、70℃に保つ。 B.成分(8)、(11)および(12)を加熱混合
し、70℃に保つ。 C.BにAを加えて乳化し、30℃まで冷却して、クリ
ームを得る。(Production Method) A. The components (1) to (7), (9) and (10) are mixed by heating and kept at 70 ° C. B. Ingredients (8), (11) and (12) are heat mixed and maintained at 70 ° C. C. Add A to B to emulsify and cool to 30 ° C. to obtain a cream.
【0033】<比較例2>組成は実施例2の組成からネ
オアガロビオースを除き、代わりに同量の精製水を加え
たものである。製法は実施例2の製法に準じたものであ
る。<Comparative Example 2> The composition is the same as that of Example 2 except that neoagarobiose is removed, and the same amount of purified water is added instead. The manufacturing method is based on the manufacturing method of Example 2.
【0034】[0034]
【表4】 [Table 4]
【0035】表4の結果より明らかなように、実施例2
のクリームは比較例2のものに比べ、シミ、ソバカス、
くすみの解消において良好な結果が得られ、優れた美白
効果を示した。As is clear from the results shown in Table 4, Example 2
Compared to the cream of Comparative Example 2, the cream of spots, freckles,
Good results were obtained in eliminating dullness, and an excellent whitening effect was exhibited.
【0036】実施例3および比較例3 化粧水 下に示す組成および製法で化粧水を調製し、その保湿作
用による肌荒れ改善効果を、使用試験により評価した。
評価方法および評価基準は、実施例1および比較例1の
方法と同じである。結果を表5に示す。Example 3 and Comparative Example 3 Lotion A lotion was prepared by the composition and production method shown below, and the effect of moisturizing skin roughening was evaluated by a use test.
The evaluation method and evaluation criteria are the same as those in Example 1 and Comparative Example 1. The results are shown in Table 5.
【0037】<実施例3> (組成) (成 分) (重量%) (1)グリセリン 2.5 (2)1,3−ブチレングリコール 3.5 (3)オレイルアルコール 0.1 (4)ポリオキシエチレンソルビタン モノラウリン酸エステル(20E.O.) 1.5 (5)ポリオキシエチレンラウリルエーテル(20E.O.) 0.5 (6)エチルアルコール 13 (7)ソルビトール 1 (8)ネオアガロビオース(注1と同じもの) 0.01 (9)ビタミンE 0.1 (10)オキシベンゾン 0.2 (11)防腐剤 適 量 (12)香料 適 量 (13)精製水 残 量<Example 3> (Composition) (Component) (wt%) (1) Glycerin 2.5 (2) 1,3-butylene glycol 3.5 (3) Oleyl alcohol 0.1 (4) Poly Oxyethylene sorbitan monolaurate (20EO) 1.5 (5) Polyoxyethylene lauryl ether (20EO) 0.5 (6) Ethyl alcohol 13 (7) Sorbitol 1 (8) Neoagarobiose (Same as Note 1) 0.01 (9) Vitamin E 0.1 (10) Oxybenzone 0.2 (11) Preservative Suitable amount (12) Perfume Suitable amount (13) Purified water Residual amount
【0038】(製法) A.成分(3)〜(6)および(9)〜(12)を混合
溶解する。 B.成分(1)、(2)、(7)、(8)および(1
3)を混合溶解する。 C.AとBを混合して均一にし、化粧水を得る。(Production Method) A. Components (3) to (6) and (9) to (12) are mixed and dissolved. B. Components (1), (2), (7), (8) and (1
Mix and dissolve 3). C. Mix A and B to make uniform and obtain lotion.
【0039】<比較例3>組成は実施例3の組成からネ
オアガロビオースを除き、代わりに同量の精製水を加え
たものである。製法は実施例3の製法に準じたものであ
る。<Comparative Example 3> The composition is the same as that of Example 3, except that neoagarobiose was removed, and the same amount of purified water was added instead. The manufacturing method is based on the manufacturing method of Example 3.
【0040】[0040]
【表5】 [Table 5]
【0041】表5の結果より明らかなように、実施例3
の化粧水は比較例3のものに比べ、肌のかさつき、荒れ
の改善において良好な結果が得られ、保湿による肌荒れ
改善効果に優れた効果を示した。As is clear from the results in Table 5, Example 3
As compared with Comparative Example 3, the lotion of No. 3 gave good results in improving the bulkiness and roughness of the skin, and showed an excellent effect of improving skin roughness by moisturizing.
【0042】実施例4および比較例4 ヘアシャンプ
ー 下に示す組成および製法でヘアシャンプーを調製し、使
用試験を行って、その毛髪保湿効果を下記評価方法およ
び評価基準により評価した。結果を表6に示す。Example 4 and Comparative Example 4 Hair Shampoo A hair shampoo was prepared according to the composition and production method shown below, and a usage test was conducted to evaluate the moisturizing effect of hair according to the following evaluation methods and evaluation criteria. The results are shown in Table 6.
【0043】<実施例4> (組成) (成 分) (重量%) (1)ラウリル硫酸トリエタノールアミン 16 (2)ラウリン酸ジエタノールアミド 4 (3)プロピレングリコール 2 (4)防腐剤 適 量 (5)香料 適 量 (6)ネオアガロビオース(注1と同じもの) 1.5 (7)精製水 残 量<Example 4> (Composition) (Component) (% by weight) (1) Lauryl sulfate triethanolamine 16 (2) Lauric acid diethanolamide 4 (3) Propylene glycol 2 (4) Preservative proper amount ( 5) Appropriate amount of fragrance (6) Neo agarobiose (same as Note 1) 1.5 (7) Residual amount of purified water
【0044】(製法) A.成分(1)〜(5)を混合溶解する。 B.成分(6)および(7)を混合溶解する。 C.AにBを加えて均一に混合し、ヘアシャンプーを得
る。(Production Method) A. Components (1) to (5) are mixed and dissolved. B. Components (6) and (7) are mixed and dissolved. C. Add B to A and mix evenly to obtain a hair shampoo.
【0045】<比較例4>組成は実施例4の組成からネ
オアガロビオースを除き、代わりに同量の精製水を加え
たものである。製法は実施例4の製法に準じたものであ
る。<Comparative Example 4> The composition is the composition of Example 4 except that neoagarobiose is removed, and the same amount of purified water is added instead. The manufacturing method is based on the manufacturing method of Example 4.
【0046】(評価方法)25〜45才の20名の女性
をパネルとし、実施例4、比較例4のヘアシャンプー2
品について、5日間にわたって毎日1回洗髪してもらっ
た。洗髪による毛髪保湿効果を下の評価基準によって評
価した。(Evaluation method) Hair shampoo 2 of Example 4 and Comparative Example 4 with 20 women aged 25 to 45 as panels
The product was washed once a day for 5 days. The moisturizing effect of hair washing was evaluated according to the following evaluation criteria.
【0047】(評価基準) [毛髪保湿効果] 有 効 : 毛髪のしっとり感が増し、髪が滑らかに
なった。 やや有効 : 毛髪のしっとり感がやや増し、髪がやや
滑らかになった。 無 効 : 変わらない(Evaluation Criteria) [Hair Moisturizing Effect] Effectiveness: The moist feeling of the hair was increased and the hair became smooth. Slightly effective: The moist feeling of the hair was slightly increased, and the hair became slightly smooth. Ineffective: Does not change
【0048】[0048]
【表6】 [Table 6]
【0049】表6の結果より明らかなように、実施例4
のヘアシャンプーは比較例4のものに比べ、髪のしっと
り感の付与において良好な結果が得られ、優れた毛髪保
湿効果を示した。As is clear from the results of Table 6, Example 4
The hair shampoo of No. 3 gave better results in imparting a moisturizing feeling to the hair and showed an excellent moisturizing effect on hair, as compared with the hair shampoo of Comparative Example 4.
【0050】実施例5 パック 下に示す組成および製法でパックを調製した。 <実施例5> (組成) (成 分) (重量%) (1)ポリビニルアルコール 15 (2)カルボキシメチルセルロースナトリウム 5 (3)プロピレングリコール 3 (4)ネオアガロビオース(注1と同じもの) 5 (5)エチルアルコール 10 (6)オキシベンゾン 0.1 (7)防腐剤 適 量 (8)香料 適 量 (9)精製水 残 量Example 5 Pack A pack was prepared with the following composition and production method. <Example 5> (Composition) (Component) (% by weight) (1) Polyvinyl alcohol 15 (2) Sodium carboxymethyl cellulose 5 (3) Propylene glycol 3 (4) Neo agarobiose (the same as Note 1) 5 (5) Ethyl alcohol 10 (6) Oxybenzone 0.1 (7) Preservative proper amount (8) Perfume proper amount (9) Purified water balance
【0051】(製法) A.成分(1)〜(4)および(9)を混合し、攪拌し
ながら70℃にて加熱溶解する。 B.成分(5)〜(7)および(8)を混合溶解する。 C.AにBを加え、均一に混合した後冷却して、パック
を得る。(Production Method) A. Components (1) to (4) and (9) are mixed and dissolved by heating at 70 ° C. with stirring. B. Components (5) to (7) and (8) are mixed and dissolved. C. B is added to A, mixed uniformly, and then cooled to obtain a pack.
【0052】以上のようにして得られた実施例5のパッ
クは、シミ、ソバカス、くすみの解消や肌のかさつき、
荒れの改善において良好な結果が得られた。The pack of Example 5 obtained as described above was used to eliminate spots, freckles, dullness, and skin roughness.
Good results were obtained in improving roughness.
【0053】[0053]
【発明の効果】以上詳述した如く、本発明の外用剤は皮
膚の美白効果、皮膚および毛髪の保湿効果において優れ
た性質を示す。As described above in detail, the external preparation of the present invention exhibits excellent properties in whitening the skin and moisturizing the skin and hair.
フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 7/075 A61K 7/075 31/70 ADA 31/70 ADA Continuation of front page (51) Int.Cl. 6 Identification code Office reference number FI Technical display area A61K 7/075 A61K 7/075 31/70 ADA 31/70 ADA
Claims (3)
とする外用剤。1. An external preparation characterized by containing neo-agarobiose.
ることを特徴とする請求項1記載の外用剤。2. The external preparation according to claim 1, which contains neo-agarobiose as a whitening agent.
ることを特徴とする請求項1記載の外用剤。3. The external preparation according to claim 1, which contains neo-agarobiose as a moisturizing agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13871895A JP3505003B2 (en) | 1995-05-12 | 1995-05-12 | External preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13871895A JP3505003B2 (en) | 1995-05-12 | 1995-05-12 | External preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08310937A true JPH08310937A (en) | 1996-11-26 |
JP3505003B2 JP3505003B2 (en) | 2004-03-08 |
Family
ID=15228524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13871895A Expired - Lifetime JP3505003B2 (en) | 1995-05-12 | 1995-05-12 | External preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3505003B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1313031C (en) * | 1999-05-14 | 2007-05-02 | 宝生物工程株式会社 | Agarobiose-contg. composition |
JP2007269636A (en) * | 2006-03-30 | 2007-10-18 | Kose Corp | Interleukin 6 production inhibitor |
JP2009102279A (en) * | 2007-10-25 | 2009-05-14 | Kose Corp | Anti-wrinkle agent and external preparation for skin to prevent formation of wrinkle |
JP2012121910A (en) * | 2012-03-05 | 2012-06-28 | Kose Corp | Interleukin 6 production inhibitor |
CN109731001A (en) * | 2019-02-13 | 2019-05-10 | 蓝脑科技(厦门)有限公司 | The newly new application of fine jade oligosaccharides and the composition containing new fine jade oligosaccharides |
CN110960439A (en) * | 2019-12-31 | 2020-04-07 | 蓝脑科技(厦门)有限公司 | Agar oligosaccharide-oligopeptide composition, preparation method and composition for repairing skin inflammation |
-
1995
- 1995-05-12 JP JP13871895A patent/JP3505003B2/en not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1313031C (en) * | 1999-05-14 | 2007-05-02 | 宝生物工程株式会社 | Agarobiose-contg. composition |
JP2007269636A (en) * | 2006-03-30 | 2007-10-18 | Kose Corp | Interleukin 6 production inhibitor |
JP2009102279A (en) * | 2007-10-25 | 2009-05-14 | Kose Corp | Anti-wrinkle agent and external preparation for skin to prevent formation of wrinkle |
JP2012121910A (en) * | 2012-03-05 | 2012-06-28 | Kose Corp | Interleukin 6 production inhibitor |
CN109731001A (en) * | 2019-02-13 | 2019-05-10 | 蓝脑科技(厦门)有限公司 | The newly new application of fine jade oligosaccharides and the composition containing new fine jade oligosaccharides |
CN110960439A (en) * | 2019-12-31 | 2020-04-07 | 蓝脑科技(厦门)有限公司 | Agar oligosaccharide-oligopeptide composition, preparation method and composition for repairing skin inflammation |
CN110960439B (en) * | 2019-12-31 | 2022-05-10 | 蓝脑科技(厦门)有限公司 | Agar oligosaccharide-oligopeptide composition, preparation method and composition for repairing skin inflammation |
Also Published As
Publication number | Publication date |
---|---|
JP3505003B2 (en) | 2004-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1600143B1 (en) | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE | |
EP2116224B1 (en) | Cosmetic composition | |
JP3513873B2 (en) | External preparation for skin | |
WO2002060395A1 (en) | Cosmetics | |
JP3513872B2 (en) | External preparation for skin | |
JP3758794B2 (en) | Collagen production promoter and anti-aging skin external preparation containing the same | |
JPH0859450A (en) | External preparation for skin | |
JP2015040173A (en) | External preparation for skin | |
JP3505003B2 (en) | External preparation | |
JP2003137768A (en) | Antiaging agent | |
JP3278138B2 (en) | External preparation for skin | |
JPH1029927A (en) | Antiaging agent | |
JP5226200B2 (en) | Sulfated glycosaminoglycan production promoter and skin external preparation containing the same | |
JP3507635B2 (en) | Composition suitable for external use | |
JP3083105B2 (en) | Cosmetics | |
JP2004097999A (en) | Emulsifier and cosmetic | |
JP4500906B2 (en) | Cosmetic compounding agent and cosmetics containing the same | |
JP4621958B2 (en) | Cosmetic compounding agent and cosmetics containing the same | |
JP2003252743A (en) | Tyrosinase activity inhibitor, melanogenesis inhibitor and skin care preparation containing them | |
JP2000143485A (en) | Composition for controlling aging of dermal cell | |
JP2001039816A (en) | Inhibitor against formation of crosslink in collagen | |
JP3526806B2 (en) | Cosmetics | |
JPH0529322B2 (en) | ||
JP2005247732A (en) | External preparation for skin | |
JP2001172160A (en) | Skin preparation for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20031212 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131219 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |